SOME £45m was secured by cannabis companies on the London markets last year with this expected to grow in 2020.
And, the new decade has gotten underway with a bang with the launch of a new medical cannabis fund, JPD Capital.
This has been founded by Jon-Paul Doran. He is the founder of UK medicinal cannabis company Eco Equity, which has attracted investment from the UK, the Middle East and Europe.
Research from stock broker Liberum calculated total fundraising in the UK cannabis sector totalled some £45m in 2019
One of the most high profile London launches was driven by Canadian investor David Stadnyk, one of the founders of Supreme Cannabis.
Shortly after launching on London’s NEX Exchange his company Wold High Life spent £9m on the UK company Love Hemp.
Medical cannabis and CBD firm Cannaray raised almost £8m and is said to be aiming for a £100m float.
UK medical cannabis firm Eco Equity raised £5m in London capital markets, last year, to create a medical cannabis cultivation business in Zimbabwe and to invest in Carbena dispensaries.
Now its founder Jon-Paul Doran has launched an exclusively medical cannabis fund, JPD Capital.
Minimum investment into the medical cannabis fund is £25,000 and investors can be based anywhere in the world. The fund is domiciled in Guernsey with marketing offices in London.
It states its aim is to invest in entities ranging from greenhouse to lighting, seed to cultivation, agricultural suppliers to distribution and companies that play a huge part in the ‘seed to sale’ journey.
Jon-Paul Doran, founder of JPD Capital, said: “I am delighted to be launching our medicinal cannabis fund in the UK. The success of our pharmaceutical arm Eco Equity over the past 18 months shows there is appetite for investment in the industry.
“The cannabis market is the fastest-growing market of 2019, proving its unstoppable growth and obvious attraction for investors.
“We want our investors to feel confident and we want our investors to see returns, as well as achieving our main aim of finding alternative and natural treatments for life-threatening illnesses.”
With the Canadian cannabis markets in financial lockdown due to on-going under-performance issues Europe may well be the beneficiary of a new wave of investment.
